Prenetics / 晶泰 新闻核实：

News Verification $XTALPI(02228.HK) 

The news content you mentioned is largely accurate, as I have cross-verified it through multiple reliable sources (such as official company press releases, Yahoo Finance, CoinDesk, and Business Insider). Below are the confirmation of key points and minor adjustments (based on the announcement dated October 27, 2025):

Financing Details: Prenetics $Prenetics Global(PRE.US) did announce the completion of an oversubscribed equity financing round on October 27, with an initial amount of approximately $48 million (reports vary slightly between $46.8 million and $48 million, but the official figure is $48 million). If all warrants are exercised, the total financing could reach $216 million. This financing is expected to close on October 28, subject to customary conditions.

Investor Team: The investors include several well-known institutions and individuals, such as the crypto exchange Kraken, American Ventures, Exodus $Exodus Movement(EXOD.US), XtalPi Holdings (listed in Hong Kong as $Jacobs Solutions(J.US)ingtai Holdings (2228.HK), with a market cap of approximately $6 billion, an innovator in quantum physics, AI, and pharmaceuticals), DL Holdings (1709.HK), GPTX (led by Bitmain founder Jihan Wu), Bitdeer Technologies Group $Bitdeer Tech(BTDR.US), and others. Additionally, tennis star Aryna Sabalenka and Asian business leader Adrian Cheng have also increased their holdings. As you mentioned, the specific investment amount or equity stake of Jingtai Holdings has not been disclosed in public information (nor have the specific shares of other investors been detailed).

Use of Funds: The funds will primarily be used for the global expansion of the IM8 brand and to strengthen the Bitcoin reserve strategy. The company emphasized that this will further consolidate its balance sheet, providing total liquidity of $13.1 million (including Bitcoin holdings). IM8 (Prenetics' flagship consumer health brand, co-founded by David Beckham) achieved approximately $100 million in annual recurring revenue (ARR) within 11 months of its launch, with projected revenue of $180–200 million in 2026. The company plans to divest non-core business units to focus on IM8 and Bitcoin targets, aiming to achieve $1 billion in annual revenue and $1 billion in Bitcoin holdings within five years. Starting August 1, Prenetics initiated a "1 BTC per day" program and has accumulated approximately 275 BTC (worth around $31 million).

Regarding Your Speculation: This is indeed a reasonable speculation. XtalPi participated in the DeSci (Decentralized Science) summit in Singapore on September 30, 2025, organized by Bio Protocol and VitaDAO, coinciding with TOKEN2049. During the event, XtalPi, as an $8 billion Chinese pharmaceutical giant (focused on AI- and quantum physics-driven drug development), was frequently mentioned alongside figures like Arthur Hayes (a crypto legend) and Aubrey de Grey (a longevity science pioneer), discussing the future of DeSci and AI. Prenetics had publicly advanced its DeSci strategy as early as February 2025, including investments in Bitcoin ($250,000), Solana ($250,000), and Humanity Protocol's $Hyatt Hotels(H.US)yatt (H.US) token ($1 million), as well as exploring collaborations between genomics and decentralized science (such as the genomics partnership with Humanity Protocol). XtalPi's investment may stem from shared interests in the DeSci field, particularly the combination of AI-driven drug discovery and Prenetics' genomics.

Overall, the news is highly consistent, with no major discrepancies. The company's stock price may fluctuate after the announcement, but the current market response is positive (driven by the Bitcoin strategy and IM8 growth).

Detailed Overview of Prenetics

Prenetics Global Limited $Prenetics Global(PRE.US) is a health sciences company founded in 2014, headquartered in Hong Kong, and operating globally (including Hong Kong, the U.S., and international markets). It initially focused on genetic and diagnostic testing, gradually evolving into a comprehensive platform centered on consumer health, preventive medicine, and emerging technologies. Through genomics-driven innovation, the company aims to revolutionize health prevention, early detection, and treatment. Below is a detailed overview based on sources such as the company's website, PitchBook, Yahoo Finance, Crunchbase, and Reuters.

Company History and Development

Founding and Early Stage (2014–2020): Founded by Danny Yeung and Lawrence Tzang, it initially focused on genetic testing services. Using whole exome sequencing (WES) and Illumina technology, it offered pharmacogenomics (drug response), nutrigenomics (diet optimization), cancer risk assessment, and other applications. The company expanded rapidly during the COVID-19 pandemic by providing diagnostic testing services (e.g., PCR tests), which brought it significant revenue and global recognition.

IPO and Transformation (2021–2024): In 2022, it went public on NASDAQ via a SPAC (Special Purpose Acquisition Company). The company shifted from diagnostic services to a broader consumer health focus, acquiring several related businesses (e.g., genetic testing labs). By 2024, Prenetics began divesting some traditional operations to concentrate on high-growth areas.

Recent Strategic Shift (2025 Onward): The company announced a "dual-engine" strategy: consumer health (led by the IM8 brand) and Bitcoin reserves. Inspired by companies like MicroStrategy, Prenetics purchased its first 187.42 BTC (worth $20 million) in June 2025 and launched a "1 BTC per day" program. As of October 27, it held approximately 275 BTC. The company aims to hold $1 billion worth of Bitcoin by 2030 as a strategic reserve to hedge against inflation and support innovation. Simultaneously, it is advancing its DeSci strategy (as mentioned above), combining genomics with blockchain and AI to explore decentralized identity verification and early cancer detection.

Core Business and Products

Prenetics' core is genomics-driven health solutions, divided into consumer and enterprise services:

Consumer Health (IM8 Brand): The flagship product, co-founded by David Beckham, focuses on personalized health and longevity. It includes genetic testing kits, nutritional supplements, and a health-tracking app. IM8 grew rapidly after its 2024 launch, achieving $100 million in ARR within 11 months, with a target of $180–200 million in 2026. The company plans global expansion, including entry into the U.S. and Asian markets.

Diagnostic and Preventive Services: Offers cancer screening, genetic risk assessment, and drug compatibility testing. Uses AI and big data to analyze user DNA for disease prevention.

DeSci and Crypto Integration: Partners with Humanity Protocol to use blockchain for secure genomic data storage and identity verification. Invests in crypto assets as reserves and supports DeSci projects like AI-driven cancer research.

Other Businesses: Initially involved in COVID-19 testing (partially divested) and B2B diagnostic services. The company is divesting non-core units to focus on IM8 and Bitcoin.

Financial and Market Performance

Revenue Sources: Primarily from consumer product sales (IM8 being the largest contributor) and diagnostic services. 2024 revenue was approximately several hundred million dollars, with strong growth expected in 2025 driven by IM8.

Market Cap and Stock: As of October 28, 2025, the cap is approximately several hundred million dollars (highly volatile due to crypto market influence). Stock symbol PRE, driven by Bitcoin prices and health tech trends.

Key Metrics (based on mid-2025 report):

Leadership and Partners

Key Figures: CEO Danny Yeung (founder, tech entrepreneur); Co-founder Lawrence Tzang (Chief Scientist). David Beckham serves as brand ambassador and investor, providing global influence.

Partners: Include Kraken, Exodus, XtalPi, Bitdeer (from the latest funding round). In DeSci, collaborations with Humanity Protocol, VitaDAO, etc.

Risks and Outlook

Strengths: Unique position at the intersection of health tech and DeSci due to genomics expertise and crypto strategy. IM8 shows strong growth; DeSci trend rising.

Risks: Dependence on Bitcoin price volatility; regulatory challenges (genomic data privacy, crypto investments); intense competition (23andMe, Illumina, etc.).

Outlook: The company positions itself as the "fastest-growing global consumer health company," aiming for breakthroughs in longevity science via DeSci and AI. The latest funding strengthens its dual-track strategy and may drive stock price gains.